


Supplementary Figure S4.



**Supplementary Figure S4. Seribantumab inhibits phosphorylation of HER2, HER3 and downstream effectors in HCC-95 cells.** The *NRG1* amplified cell line HCC-95 was treated with seribantumab for 3 h and then the phosphorylation status of the indicated proteins determined by Western blotting. Immunoblotting was conducted twice and representative immunoblots are shown.